Year-end Sale % OFF 
Abstract
Background: The aim of this study was to simplify and identify the contents of the herbal formula, HBX-5. This study was carried out to evaluate the therapeutic effects of HBX-6 in a mouse model of benign prostatic hyperplasia (BPH). Based on in vitro, we selected a candidate, reconstituted an experimental agent and investigated the effects on testosterone-induced BPH rats. Cell viability was determined by MTT assay in RWPE-1 and WPMY-1 cells. The expression of androgen receptor (AR) was measured in dihydrotestosterone-stimulated RWPE-1 and WPMY-1 cells. BPH was induced in mice by a subcutaneous injection of testosterone propionate for four weeks. Animals were divided into six groups: Group 1, control mice; Group 2, mice with BPH; Group 3, mice with BPH treated with finasteride; Group 4, mice with BPH treated with 200 mg/kg HBX-5; Group 5, mice with BPH treated with 100 mg/kg HBX-6; and Group 6, mice with BPH treated with 200 mg/kg HBX-6. Changes in prostate weight were measured after treatments, and the thickness of the epithelium was evaluated. The expression levels of proteins associated with prostatic cell proliferation and cell cycle-related proteins were determined. Based on previous reports and in vitro results, we selected Cornus officinalis and Psoralea corylifolia among HBX-5 components and reconstituted the experimental agent, and named it HBX-6. The result represented a new herbal formula, HBX-6 that suppressed the pathological alterations in BPH and showed a marked reduction in proliferation-related protein expression compared to mice with BPH. Our results indicate that HBX-6 has a better therapeutic effect in the BPH murine model than those of HBX-5 and finasteride, suggesting the role of HBX-6 as a new BPH remedial agent.
Highlights
Benign prostatic hyperplasia (BPH) is one of the most frequently reported male health disorders, and has a considerable impact on men older than 50 years worldwide
benign prostatic hyperplasia (BPH) is defined as a nonmalignant overgrowth prostate condition, which is implicated in lower urinary tract symptoms (LUTS) and bladder outlet obstruction (BOO) [2,3]
Our study presents the possibility of treatment of BPH by the antiproliferative effect of new combined formula, HBX-6
Summary
Benign prostatic hyperplasia (BPH) is one of the most frequently reported male health disorders, and has a considerable impact on men older than 50 years worldwide. Most men older than 80 years are likely to experience the pathological symptoms of prostatic hyperplasia [1]. While there has been some agreement on the etiology of BPH, many researchers have reported that several risk factors, such as ageing, excessive dihydrotestosterone. One major issue in BPH research is concerned with the interaction between hormonal disturbance and cellular proliferation [6]. This study was carried out to evaluate the therapeutic effects of HBX-6 in a mouse model of benign prostatic hyperplasia (BPH). We selected a candidate, reconstituted an experimental agent and investigated the effects on testosterone-induced BPH rats. Animals were divided into six groups: Group 1, control mice; Group 2, mice with BPH; Group 3, mice with BPH treated with finasteride; Group 4, mice with BPH treated with 200 mg/kg HBX-5; Group 5, mice with
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
